title: Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study.
abstract: BACKGROUND
  We analyzed detailed characteristics and salvage treatment in 175 follicular lymphoma patients from the FL2000 study who were in progression after first-line therapy with or without addition of rituximab to chemotherapy and interferon.
  
  
  METHODS
  The impact of using autologous stem cell transplantation and/or rituximab administration at first progression was investigated, taking into account initial therapy. With a median follow up of 31 months, 3-year event free and overall survival rates after progression were 50% (95%CI 42-58%) and 72% (95%CI 64-78%), respectively.
  
  
  RESULTS
  The 3-year event free rate of rituximab re-treated patients (n=112) was 52% (95%CI 41-62%) versus 40% (95%CI 24-55%) for those not receiving rituximab second line (n=53) (P=0.075). There was a significant difference in 3-year overall survival between patients receiving autologous stem cell transplantation and those not: 92% (95%CI 78-97%) versus 63% (95%CI 51-72%) (P=0.0003), respectively. In multivariate analysis, both autologous stem cell transplantation and period of progression/relapse affected event free and overall survival.
  
  
  CONCLUSIONS
  Regardless of front-line rituximab exposure, this study supports incorporating autologous stem cell transplantation in the therapeutic approach at first relapse for follicular lymphoma patients.
authors.affiliation: Service d'Hématologie, Centre Hospitalier Lyon-Sud, Pierre-Bénite Cedex, France.
authors.forename: Steven
authors.initials: S
authors.lastname: Le Gouill
authors.forename: Sophie
authors.initials: S
authors.lastname: De Guibert
authors.forename: Lucie
authors.initials: L
authors.lastname: Planche
authors.forename: Pauline
authors.initials: P
authors.lastname: Brice
authors.forename: Jehan
authors.initials: J
authors.lastname: Dupuis
authors.forename: Guillaume
authors.initials: G
authors.lastname: Cartron
authors.forename: Achiel
authors.initials: A
authors.lastname: Van Hoof
authors.forename: Olivier
authors.initials: O
authors.lastname: Casasnovas
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Gyan
authors.forename: Hervé
authors.initials: H
authors.lastname: Tilly
authors.forename: Christophe
authors.initials: C
authors.lastname: Fruchart
authors.forename: Eric
authors.initials: E
authors.lastname: Deconinck
authors.forename: Olivier
authors.initials: O
authors.lastname: Fitoussi
authors.forename: Lauris
authors.initials: L
authors.lastname: Gastaud
authors.forename: Vincent
authors.initials: V
authors.lastname: Delwail
authors.forename: Jean
authors.initials: J
authors.lastname: Gabarre
authors.forename: Rémy
authors.initials: R
authors.lastname: Gressin
authors.forename: Michel
authors.initials: M
authors.lastname: Blanc
authors.forename: Charles
authors.initials: C
authors.lastname: Foussard
authors.forename: Gilles
authors.initials: G
authors.lastname: Salles
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D018450:Disease Progression; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008224:Lymphoma, Follicular / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012307:Risk Factors; D000069283:Rituximab; D016879:Salvage Therapy; D016019:Survival Analysis; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab